NeurogesX to Present at Needham Life Sciences ...( SAN MATEO Calif. June 3 /- Neuroges...)

SAN MATEO, Calif., June 3 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 8th Annual Needham Life Sciences Conference on Wednesday, June 10, 2009.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to questions during the breakout session immediately following the presentation and to participate in one-on-one meetings with investors attending the conference.

    Event:  8th Annual Needham Life Sciences Conference
    Date:   Wednesday, June 10, 2009
    Time:   10:00 a.m. ET
    Place:  New York Palace Hotel, New York, NY (Track 5 - Chairman's Office,
            5th Floor)

The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcast will be archived for 90 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuro
'/>"/>